Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

32.49USD
24 May 2017
Change (% chg)

-- (--)
Prev Close
$32.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
568,016
52-wk High
$63.73
52-wk Low
$14.84

SRPT.OQ

Chart for SRPT.OQ

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $1,773.40
Shares Outstanding(Mil.): 54.96
Dividend: --
Yield (%): --

Financials

  SRPT.OQ Industry Sector
P/E (TTM): -- 141.11 17.36
EPS (TTM): -2.64 -- --
ROI: -41.47 2.25 -5.72
ROE: -43.44 0.17 -5.10

Tourbillon's Karp says Sarepta shares could surge 200 percent

LAS VEGAS Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.

May 18 2017

Tourbillon's Karp says Sarepta shares could surge 200 pct

LAS VEGAS, May 18 Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.

May 18 2017

BRIEF-Sarepta Therapeutics anticipates net revenues for the year to exceed $95 mln

* Sarepta Therapeutics - in Q1, recognized net revenues of $16.3 million in product sales; no revenue was recognized for the same period of 2016

Apr 27 2017

BRIEF-Sarepta appoints Kenneth Fischbeckt to the company’s strategic and scientific advisory board

* Sarepta Therapeutics announces addition of Kenneth Fischbeck, M.D. And matthew wood M.D., Ph.D. to the company’s strategic and scientific advisory board Source text for Eikon: Further company coverage:

Mar 30 2017

BRIEF-Sarepta Therapeutics Q4 non-gaap loss per share $0.71

* Sarepta Therapeutics announces fourth quarter and full-year 2016 financial results and recent corporate developments

Feb 28 2017

BRIEF-Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln

* Sarepta Therapeutics agrees to sale of priority review voucher for $125m

Feb 21 2017

BRIEF-Sarepta Therapeutics enters into license agreement with nationwide children's hospital

* Sarepta Therapeutics enters into license agreement with nationwide children's hospital for GALGT2 gene therapy program Source text for Eikon: Further company coverage:

Jan 10 2017

More From Around the Web

Earnings vs. Estimates